Genolimzumab

杰诺单抗

Report date: 2026/04/23 20:00:25

Base Information

Drug NameGenolimzumab
Drug Alias Name杰洛利单抗GB 226CBT 501PD-1 antibody - Genor BiopharmaGeptanolimab +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursMismatch Repair Deficient CancerMicrosatellite Instability +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesApollomics IncGenor Biopharma Co LtdApollomics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEdding Genor Group Holdings LtdApollomics IncApollomics (Australia) Pty Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursMismatch Repair Deficient CancerMicrosatellite Instability +[13] 
Inactive IndicationsCarcinoma, Renal CellCarcinoma, HepatocellularLymphoma, B-Cell +[4] 

Other Information

ATC CodeN/A
Related LinksDrugBank